Royalty
Biogen Secures $250 Million R&D Funding from Royalty Pharma for Lupus Drug Litifilimab
Biogen, Royalty Pharma, litifilimab, lupus, R&D funding, Phase 3 trials, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)
Royalty Pharma Invests $250M in Biogen’s Late-Stage Lupus Treatment
Biogen, Royalty Pharma, litifilimab, lupus, Phase 3 trials, R&D funding, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)
BioNTech Resolves COVID-19 Vaccine Royalty Disputes with NIH and UPenn
BioNTech, COVID-19 vaccine, royalty disputes, NIH, UPenn, Pfizer, settlement agreements
Advancements in Bispecific Antibody Therapies: Recent Deals and Clinical Data on VEGF-Targeting Agents
Bispecific antibodies, VEGF, neovascular age-related macular degeneration (nAMD), cancer therapy, clinical trials, royalty agreements.
FDA Approves Servier’s Brain Cancer Drug, Triggering $1 Billion Payout for Agios
FDA approval, Servier, brain cancer drug, Voranigo, Agios Pharmaceuticals, IDH1 and IDH2 mutations, blood-brain barrier, cancer metabolism, royalty payments
Cytokinetics’ Royalty Agreement Dampens Merger and Acquisition Hopes, Say Investors
Cytokinetics, Merger and Acquisition (M&A), Royalty Agreement, Investors, Biotech Industry
Royalty Pharma Invests $525 Million in Sanofi-Licensed Multiple Sclerosis Therapy Royalties and Milestones
Royalty Pharma, Sanofi, multiple sclerosis therapy, royalties, milestones, investment, healthcare, pharmaceuticals, licensing